Nvidia to resume H20 GPU chip sales to Beijing, launches China-compliant model
According to a company blog post, Nvidia is filing applications to resume H20 sales with the U.S. government and expects to get the licenses soon. Deliveries are expected to begin shortly thereafter.
The company announced a new RTX Pro GPU designed specifically for China. Nvidia described the model as "fully compliant" and suitable for digital twin AI applications in sectors such as smart factories and logistics.
The chipmaker's CEO Jensen Huang met with U.S. President Donald Trump and policymakers in Washington and later with officials in Beijing, as part of efforts to promote AI cooperation and highlight Nvidia's support for open-source research and global AI development, the company said.
In May, Reuters reported that the company was planning to release a downgraded version of its H20 artificial intelligence chip for China following U.S. export restrictions on the original model.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
3 Asian Stocks Estimated To Be Trading At Up To 38.4% Below Fair Value
As global markets respond positively to new trade deals and economic indicators, Asian stocks are capturing attention with their potential value. In this environment, identifying undervalued stocks can offer opportunities for investors seeking to capitalize on discrepancies between market prices and perceived intrinsic values. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Zhuhai CosMX Battery (SHSE:688772) CN¥14.07 CN¥27.82 49.4% SpiderPlus (TSE:4192) ¥498.00 ¥993.27 49.9% Shenzhen Envicool Technology (SZSE:002837) CN¥31.65 CN¥62.15 49.1% Range Intelligent Computing Technology Group (SZSE:300442) CN¥51.51 CN¥101.65 49.3% Polaris Holdings (TSE:3010) ¥221.00 ¥433.91 49.1% HL Holdings (KOSE:A060980) ₩40950.00 ₩81254.09 49.6% HDC Hyundai Development (KOSE:A294870) ₩23000.00 ₩45711.05 49.7% GEM (SZSE:002340) CN¥6.68 CN¥13.13 49.1% Forum Engineering (TSE:7088) ¥1206.00 ¥2404.16 49.8% cottaLTD (TSE:3359) ¥433.00 ¥851.54 49.2% Click here to see the full list of 263 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Sanil Electric Overview: Sanil Electric Co., Ltd. manufactures and sells transformers in Korea and internationally, with a market cap of ₩3.01 billion. Operations: Sanil Electric's revenue is primarily derived from its Electric Equipment segment, totaling ₩362.18 million. Estimated Discount To Fair Value: 10.5% Sanil Electric, trading at ₩98,900, is considered undervalued with a fair value estimate of ₩110,444.76. The company's earnings are projected to grow significantly at 23.7% annually over the next three years, outpacing the Korean market average of 20.9%. Revenue growth is also expected to exceed market averages at 22.4% per year. Despite high non-cash earnings and a strong forecasted return on equity of 27%, its undervaluation margin remains modest at 10.5%. The analysis detailed in our Sanil Electric growth report hints at robust future financial performance. Dive into the specifics of Sanil Electric here with our thorough financial health report. BMC Medical Overview: BMC Medical Co., Ltd. focuses on the research, development, manufacturing, and supply of respiratory health medical equipment and consumables in China with a market cap of CN¥7.91 billion. Operations: The company's revenue primarily comes from its Surgical & Medical Equipment segment, which generated CN¥915.44 million. Estimated Discount To Fair Value: 36.1% BMC Medical is trading at CN¥88.99, significantly undervalued with a fair value estimate of CN¥139.29, offering potential for investors focused on cash flow valuation. Despite low forecasted return on equity of 10% in three years, its earnings are expected to grow robustly at 27.5% annually, outpacing the Chinese market's average growth rate. Recent product-related announcements highlight BMC's expanding international presence and innovation in digital health solutions, potentially enhancing future revenue streams. The growth report we've compiled suggests that BMC Medical's future prospects could be on the up. Delve into the full analysis health report here for a deeper understanding of BMC Medical. Fuji Overview: Fuji Corporation, with a market cap of ¥246.79 billion, manufactures and sells machines and machine tools in Japan. Operations: The company's revenue is primarily derived from its Robotic Solutions segment at ¥114.21 billion and Machine Tools segment at ¥11.09 billion. Estimated Discount To Fair Value: 38.4% Fuji, trading at ¥2808, is significantly undervalued with a fair value estimate of ¥4558.69. Its earnings are forecasted to grow at 20.8% annually, surpassing the Japanese market average. Despite a low future return on equity of 9.4%, revenue growth is expected to outpace the market at 9.5% per year. Recent completion of a share buyback program and stable dividend affirmations reflect strategic financial management aimed at enhancing shareholder value amidst leadership changes. Our growth report here indicates Fuji may be poised for an improving outlook. Click here to discover the nuances of Fuji with our detailed financial health report. Where To Now? Discover the full array of 263 Undervalued Asian Stocks Based On Cash Flows right here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A062040 SZSE:301367 and TSE:6134. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
14 minutes ago
- Yahoo
Undiscovered Asian Gems with Strong Potential In July 2025
As global markets reach new heights, buoyed by favorable trade deals and robust economic indicators, the Asian markets are also experiencing a wave of optimism. With recent developments in trade agreements and economic resilience, investors are increasingly looking towards small-cap stocks in Asia for their potential to capitalize on these dynamic conditions. In this environment, identifying promising companies involves assessing their ability to adapt to changing market landscapes while leveraging regional growth opportunities. Top 10 Undiscovered Gems With Strong Fundamentals In Asia Name Debt To Equity Revenue Growth Earnings Growth Health Rating AIC NA 26.88% 54.47% ★★★★★★ Toho 72.03% 6.01% 64.19% ★★★★★★ PSC 15.34% 1.17% 10.86% ★★★★★★ Nantong Guosheng Intelligence Technology Group NA 8.02% 1.71% ★★★★★★ HeXun Biosciences NA 74.95% 119.41% ★★★★★★ Zhejiang JW Precision MachineryLtd 12.36% 4.29% -22.66% ★★★★★★ Wholetech System Hitech 3.31% 15.16% 19.61% ★★★★★☆ Zhejiang Jinghua Laser TechnologyLtd 2.85% 4.02% -2.43% ★★★★★☆ Ningbo Henghe Precision IndustryLtd 66.02% 5.50% 23.91% ★★★★☆☆ Keli Motor Group 35.39% 9.99% -14.86% ★★★★☆☆ Click here to see the full list of 2601 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. We're going to check out a few of the best picks from our screener tool. Quechen Silicon Chemical Simply Wall St Value Rating: ★★★★★★ Overview: Quechen Silicon Chemical Co., Ltd. operates in the manufacture and supply of silica both in China and internationally, with a market capitalization of CN¥8.11 billion. Operations: Quechen Silicon Chemical generates revenue primarily from its Specialty Chemicals segment, amounting to CN¥2.21 billion. Quechen Silicon Chemical, a nimble player in the chemicals sector, has shown robust growth with earnings surging 23.4% over the past year, outpacing the industry's modest 4% rise. The firm is trading at a compelling value, sitting 33.4% below its estimated fair value. It boasts high-quality earnings and maintains an impressive debt-to-equity ratio that has shrunk from 9% to just 2.3% over five years. With strong free cash flow and profitability ensuring no worries about cash runway, Quechen appears well-positioned for continued growth with forecasts suggesting an annual earnings increase of nearly 11.82%. Click here and access our complete health analysis report to understand the dynamics of Quechen Silicon Chemical. Understand Quechen Silicon Chemical's track record by examining our Past report. HangzhouS MedTech Simply Wall St Value Rating: ★★★★★★ Overview: Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, production, sale, and service of endoscopic surgery equipment and accessories in China with a market cap of approximately CN¥6.65 billion. Operations: HangzhouS MedTech generates revenue primarily from the sale of endoscopic surgery equipment and accessories. The company's net profit margin has shown a notable trend, reflecting its financial health and efficiency in managing costs relative to its revenue streams. With no debt over the past five years, HangzhouS MedTech showcases financial prudence, underscored by high-quality earnings. The company's earnings growth of 25.9% in the last year significantly outpaced the Medical Equipment industry average of -2.2%. Trading at a value 24.8% below its estimated fair value, it offers an attractive proposition compared to peers and industry standards. Levered free cash flow has shown a steady rise, reaching US$267.89 million recently, hinting at robust operational efficiency despite capital expenditures of US$41.16 million in the same period. Future growth prospects appear promising with forecasted annual earnings growth of 20.76%. Dive into the specifics of HangzhouS MedTech here with our thorough health report. Explore historical data to track HangzhouS MedTech's performance over time in our Past section. Medprin Regenerative Medical Technologies Simply Wall St Value Rating: ★★★★★★ Overview: Medprin Regenerative Medical Technologies Co., Ltd. is a company specializing in the development and manufacture of innovative regenerative medical products, with a market cap of CN¥4.96 billion. Operations: Medprin Regenerative Medical Technologies generates revenue through the development and manufacture of regenerative medical products. The company's financial performance is highlighted by a notable net profit margin, reflecting its efficiency in managing costs relative to its revenue streams. Medprin Regenerative Medical Technologies, a nimble player in the medical equipment sector, showcases impressive financial health with no debt and an earnings growth of 83.5% over the past year, outpacing the industry average of -2.2%. The company has transitioned to positive levered free cash flow recently, reaching CNY 102.39 million by mid-2025 from negative figures in prior years. Despite recent share price volatility, Medprin's strategic moves include a private placement at CNY 48.03 per share to raise funds for asset purchases and operational support, reflecting robust shareholder confidence and positioning it well for future endeavors. Delve into the full analysis health report here for a deeper understanding of Medprin Regenerative Medical Technologies. Gain insights into Medprin Regenerative Medical Technologies' past trends and performance with our Past report. Taking Advantage Take a closer look at our Asian Undiscovered Gems With Strong Fundamentals list of 2601 companies by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:605183 SHSE:688581 and SZSE:301033. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Asian shares are mixed after Wall Street sets more records for US stocks
BANGKOK (AP) — Stock markets in Asia were mixed on Monday after U.S. stocks rose to more records as they closed out another winning week. U.S. futures and oil prices were higher ahead of trade talks in Stockholm between U.S. and Chinese officials. European futures rose after the European Union forged a deal with the Trump administration calling for 15% tariffs on most exports to the U.S. The agreement announced after President Donald Trump and European Commission chief Ursula von der Leyen met briefly at Trump's Turnberry golf course in Scotland staves off far higher import duties on both sides that might have sent shock waves through economies around the globe. Tokyo's Nikkei 225 index lost 1% to 41,056.81 after doubts surfaced over what exactly the trade truce between Japan and U.S. President Donald Trump, especially the $550 billion pledge of investment in the U.S. by Japan, will entail. Terms of the deal are still being negotiated and nothing has been formalized in writing, said an official, who insisted on anonymity to detail the terms of the talks. The official suggested the goal was for a $550 billion fund to make investments at Trump's direction. Hong Kong's Hang Seng index gained 0.4% to 25,490.45 while the Shanghai Composite index lost 0.2% to 3,587.25. Taiwan's Taiex rose 0.3%. CK Hutchison, a Hong Kong conglomerate that's selling ports at the Panama Canal, said it may seek a Chinese investor to join a consortium of buyers in a move that might please Beijing but could also bring more U.S. scrutiny to a geopolitically fraught deal. CK Hutchison's shares fell 0.6% on Monday in Hong Kong. Elsewhere in Asia, South Korea's Kospi was little changed at 3,195.49, while Australia's S&P/ASX 200 rose 0.3% to 8,688.40. India's Sensex slipped 0.1%. Markets in Thailand were closed for a holiday. On Friday, the S&P 500 rose 0.4% to 6,388.64, setting an all-time for the fifth time in a week. The Dow Jones Industrial Average climbed 0.5% to 44,901.92, while the Nasdaq composite added 0.2%, closing at 21,108.32 to top its own record. Deckers, the company behind Ugg boots and Hoka shoes, jumped 11.3% after reporting stronger profit and revenue for the spring than analysts expected. Its growth was particularly strong outside the United States, where revenue soared nearly 50%. But Intell fell 8.5% after reporting a loss for the latest quarter, when analysts were looking for a profit. The struggling chipmaker also said it would cut thousands of jobs and eliminate other expenses as it tries to turn around its fortunes. Intel, which helped launch Silicon Valley as the U.S. technology hub, has fallen behind rivals like Nvidia and Advanced Micro Devices while demand for artificial intelligence chips soars. Companies are under pressure to deliver solid growth in profits to justify big gains for their stock prices, which have rallied to record after record in recent weeks. Wall Street has zoomed higher on hopes that President Donald Trump will reach trade deals with other countries that will lower his stiff proposed tariffs, along with the risk that they could cause a recession and drive up inflation. Trump has recently announced deals with Japan and the Philippines, and the next big deadline is looming on Friday, Aug. 1. Apart from trade talks, this week will also feature a meeting by the Federal Reserve on interest rates. Trump again on Thursday lobbied the Fed to cut rates, which he has implied could save the U.S. government money on its debt repayments. Fed Chair Jerome Powell has said he is waiting for more data about how Trump's tariffs affect the economy and inflation before making a move. The widespread expectation on Wall Street is that the Fed will wait until September to resume cutting interest rates. In other dealings early Monday, U.S. benchmark crude oil gained 24 cents to $65.40 per barrel. Brent crude, the international standard, also added 24 cents to $67.90 per barrel. The dollar rose to 147.72 Japanese yen from 147.71 yen. The euro slipped to $1.1755 from $1.1758.
